Brage HiM
Not a member yet
2978 research outputs found
Sort by
Development of a webapplication for Rogaland Brann og Redning IKS, Alarm Center 110 South-West
Full text linkKognitiv atferdsterapi for insomni (CBT-i) som tilnærmingsmetode ved søvnvansker og depresjon
Full text linkEmotional Stress among Healthcare Personnel in Home Care Services: Measures to Reduce Strain in Challenging Situations
Full text linkThe association between serum 25-hydroxyvitamin D levels and psoriasis in a large population-based cohort: a cross-sectional analysis of The Tromsø Study 2015–16
Full text linkBackground
Case–control studies indicate an association between lower serum 25-hydroxyvitamin D [25(OH)D] levels and psoriasis. Data from larger population-based cohorts including mild cases are sparse.
Objectives
To investigate the association between 25(OH)D and psoriasis in a large population-based cohort, and assess possible effect modification by overweight.
Methods
Data from the Tromsø Study 2015–16 (Tromsø7), which included 19 520 participants from the general population aged 40–79 years, were subjected to a cross-sectional analysis. We assessed the shapes of the relationships between 25(OH)D and psoriasis using fractional polynomials. Odds ratios (ORs) for lifetime and active psoriasis were estimated using logistic regression. Adjusted models included month of blood sampling, body mass index (BMI), age and sex. Two-way and additive interaction between BMI and 25(OH)D were explored.
Results
From a total of 19 520 participants [10 203 women (52.3%); mean age 56.3 years (SD 10.4); mean 25[OH]D, 63.4 nmol L−1 (SD 21.9)], 2088 (10.7%) reported lifetime psoriasis and 1179 (6.0%) reported active psoriasis the past 12 months. There was no association between 25(OH)D and lifetime psoriasis [OR per 10 nmol L−1 increase in 25(OH)D 1.02, 95% confidence interval (CI) 0.99–1.04]. The relationship between 25(OH)D and active psoriasis was suggested to be nonlinear, but the model was not significant (P = 0.098). There was evidence for a superadditive effect (i.e. larger than the sum of the factors) of BMI > 27.5 kg m−2 and 25(OH)D < 25 nmol L−1 on the odds for active psoriasis (OR 1.92, 95% CI 1.18–3.12), but not for lifetime psoriasis (OR 1.41, 95% CI 0.93–2.15). There was no evidence for two-way interaction between BMI and 25(OH)D.
Conclusions
This large population-based study found no significant relationship between 25(OH)D and psoriasis. The analysis may have been underpowered to detect a threshold effect in the lower 25(OH)D spectrum. Interaction analysis indicates that high BMI and vitamin D deficiency combined increase the odds of active psoriasis more than the sum of these factors, with an estimated 92% higher odds for active psoriasis in participants with BMI > 27.5 kg m−2 and 25(OH)D < 25 nmol L−1. Providing advice to prevent vitamin D deficiency may be considered in the follow-up of overweight patients with psoriasis.publishedVersio
